BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Asthma clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for asthma: 145 (72 sponsors; 29 newly posted in the last 180 days, 10 stopped in the last 180 days; 10 new-entrant sponsors). Momentum score 19, rank 31 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 14, Phase 2 39, Phase 3 43, Phase 4 6, N/A 43.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 30 | P3 8, NA 19, P2 2, P4 1 | 3 | 4 |
| GlaxoSmithKline | 12 | P3 7, P4 2, P1 2, P2 1 | 5 | 5 |
| Inmunotek S.L. | 7 | P3 7 | 2 | 1 |
| Chiesi Farmaceutici S.p.A. | 5 | P2 1, P4 1, P1 1, P3 2 | 3 | 0 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 5 | P3 2, P2 2, P1 1 | 1 | 1 |
| Novartis Pharmaceuticals NVS | 5 | P3 2, NA 2, P2 1 | 0 | 2 |
| Pfizer PFE | 4 | P1 1, P3 2, P2 1 | 3 | 2 |
| Generate Biomedicines GENB | 3 | P1 1, P3 2 | 0 | 1 |
| Sanofi SNY | 5 | P2 2, NA 1, P4 1, P3 1 | 0 | 1 |
| Shanghai Mabgeek Biotech.Co.Ltd | 2 | P2 1, P3 1 | 0 | 0 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | 2 | P2 1, P3 1 | 0 | 2 |
| Areteia Therapeutics | 1 | P3 1 | 0 | 0 |
| CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Daewon Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Lunan Better Pharmaceutical Co., LTD. new entrant | 1 | P3 1 | 1 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Teva Branded Pharmaceutical Products R&D LLC | 1 | P3 1 | 0 | 1 |
| Amgen AMGN | 2 | P1 2 | 1 | 2 |
| Anhui Palo Alto Pharmaceuticals, Inc. | 2 | P2 2 | 0 | 0 |
| Chiesi Hungary Ltd. | 2 | NA 2 | 0 | 0 |
| Kymera Therapeutics, Inc. KYMR | 2 | P2 2 | 1 | 0 |
| Acurable Ltd. | 1 | NA 1 | 0 | 0 |
| Adhera Health, Inc. new entrant | 1 | NA 1 | 1 | 0 |
New-entrant sponsors: Lunan Better Pharmaceutical Co., LTD., Adhera Health, Inc..
Recently stopped trials
- NCT01987492 Hoffmann-La Roche - terminated: Sponsor decision to discontinue lebrikizumab development for the treatment of asthma. A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
- NCT07318350 Eurofarma Laboratorios S.A. - withdrawn: Strategic change in development priorities. Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients Wi
- NCT06033833 Sanofi - terminated: Sponsor decision; the decision is not related to any safety concern. Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthm
- NCT02192736 Translational Biosciences - terminated: Did not meet recruitment goals Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma
- NCT05292950 Arrowhead Pharmaceuticals - terminated: Sponsor business decision Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
- NCT04963140 Restech Srl - terminated: The study was terminated early due to an unexpected difficulty at the study sites in recruiting patients who met all the inclusion criteria. Self-Management Of Asthma By Forced Oscillation Technique
- NCT06376045 Amgen - terminated: Sponsor Decision A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
- NCT07408869 Candid Therapeutics - withdrawn: Sponsor decision A Phase 1 Study of Cizutamig in IgE Mediated Diseases
- NCT01875003 Hoffmann-La Roche - terminated: Sponsor decision to discontinue lebrikizumab development for the treatment of asthma. A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Sec
- NCT05398263 AstraZeneca - terminated: The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral cort Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P2 | Incyte Corporation INCY | NCT05851443 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Moderate to Severe Asthma | active not recruiting | 247 |
| 2026-12 est. | P3 | Inmunotek S.L. | NCT04435990 Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites | Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic | recruiting | 150 |
| 2026-12 est. | P2 | Enveda Therapeutics | NCT07301255 ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults | Asthma | recruiting | 50 |
| 2026-12 est. | P2 | Connect Biopharm LLC CNTB | NCT07705737 Rademikibart IV for Acute Asthma and COPD Exacerbation | Asthma Acute; COPD Exacerbation Acute | recruiting | 40 |
| 2026-12-23 est. | P3 | AstraZeneca AZN | NCT05692180 A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizum | Asthma | active not recruiting | 94 |
| 2026-12-27 est. | P2 | Akeso | NCT07436221 A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma | Asthma | not yet recruiting | 160 |
| 2026-12-28 est. | P3 | GlaxoSmithKline | NCT07645248 A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | Asthma | recruiting | 110 |
| 2026-12-31 est. | P3 | Teva Branded Pharmaceutical Products R&D LLC | NCT06052267 A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Asthma | active not recruiting | 2769 |
| 2027-01-26 est. | P3 | GlaxoSmithKline | NCT05757102 A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Asthma | active not recruiting | 138 |
| 2027-02 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06323213 Efficacy and Safety Study of 610 in Patients With Severe Asthma | Asthma | recruiting | 480 |
| 2027-02 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06680947 A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma | Asthma | active not recruiting | 225 |
| 2027-02 est. | P1/P2 | RIGImmune Inc. | NCT07488897 RIG 101 Trial in Healthy Adults and Adults With Asthma | Healthy Adult Participants; Asthma Exacerbation; Safety and Efficacy | recruiting | 82 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-26 | P3 | Teva Branded Pharmaceutical Products R&D LLC | NCT06664619 A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and | Asthma | completed | 649 |
| 2026-10-01 est. | P1/P2 | Prana Therapies Inc | NCT07245368 Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Mild to Moderate Asthma | recruiting | 96 |
| 2026-10 est. | P2 | Advagene Biopharma Co. Ltd. | NCT07250594 A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma | Eosinophilic Asthma | not yet recruiting | 126 |
| 2026-10 est. | P3 | Inmunotek S.L. | NCT04898283 Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. | Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic | recruiting | 180 |
| 2026-09-22 | P2 | Sanofi SNY | NCT06033833 Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Prev | Asthma | terminated | 335 |
| 2026-09-21 | P3 | AstraZeneca AZN | NCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated | Eosinophilic Asthma | completed | 130 |
| 2026-09-01 | P2 | Ethris GmbH | NCT07059767 Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge | Asthma (Diagnosis) | completed | 50 |
| 2026-08-31 est. | P3 | Daewon Pharmaceutical Co., Ltd. | NCT07168473 Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma | Perennial Allergic Rhinitis Accompanied by Asthma | recruiting | 274 |
| 2026-08-03 | P2 | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | NCT07807007 Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma | Asthma | completed | 150 |
| 2026-07-17 | P2 | Connect Biopharm LLC CNTB | NCT06940141 Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) | Asthma Acute | completed | 160 |
| 2026-07-14 | P2 | GlaxoSmithKline | NCT06748053 A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma | Asthma | active not recruiting | 307 |
| 2026-07-06 | P2 | Uniquity One (UNI) | NCT06496607 A Study to Evaluate Solriktug in Adult Participants With Asthma | Asthma | completed | 145 |
| 2026-06-01 est. | P2/P3 | Inmunotek S.L. | NCT05641272 Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract | Allergic Rhinitis; Allergic Asthma; Allergic Rhinoconjunctivitis; Allergy to House Dust Mite | not yet recruiting | 90 |
| 2026-05-26 est. | P2 | Shanghai Mabgeek Biotech.Co.Ltd | NCT07054034 Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects | Bronchial Asthma | active not recruiting | 160 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "asthma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.